Updated results of NORDIC 8, a randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer

P. Pfeiffer; J. K. Bjerregaard; C. Qvortrup; H. Sorbye; B. Glimelius; C. Kersten

doi:10.1093/annonc/mdz246.027

Updated results of NORDIC 8, a randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer

P. Pfeiffer
, J. K. Bjerregaard
, C. Qvortrup
, H. Sorbye
, B. Glimelius
, C. Kersten

KI, OUH, Forskningsenhed for Onkologi (Odense)

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

Originalsprog	Engelsk
Artikelnummer	550P
Tidsskrift	Annals of Oncology
Vol/bind	30
Udgave nummer	Suppl. 5
Sider (fra-til)	208
Antal sider	1
ISSN	0923-7534
DOI	https://doi.org/10.1093/annonc/mdz246.027
Status	Udgivet - okt. 2019
Begivenhed	44th Congress of the European Society for Medical Oncology - Barcelona, Spanien Varighed: 27. sep. 2019 → 1. okt. 2019

Konference

Konference	44th Congress of the European Society for Medical Oncology
Land/Område	Spanien
By	Barcelona
Periode	27/09/2019 → 01/10/2019

Dokumenter og links

10.1093/annonc/mdz246.027

SDU link

Tjek adgangen til materialet i Syddansk Universitetsbiblioteks søgemaskine

Citationsformater

Pfeiffer, P., Bjerregaard, J. K., Qvortrup, C., Sorbye, H., Glimelius, B., & Kersten, C. (2019). Updated results of NORDIC 8, a randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer. Annals of Oncology, 30(Suppl. 5), 208. Artikel 550P. https://doi.org/10.1093/annonc/mdz246.027

@article{3f2efbb7082543f999d27d8e004fe3f3,

title = "Updated results of NORDIC 8, a randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer",

author = "P. Pfeiffer and Bjerregaard, \{J. K.\} and C. Qvortrup and H. Sorbye and B. Glimelius and C. Kersten",

year = "2019",

month = oct,

doi = "10.1093/annonc/mdz246.027",

language = "English",

volume = "30",

pages = "208",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier",

number = "Suppl. 5",

note = "44th Congress of the European Society for Medical Oncology, ESMO ; Conference date: 27-09-2019 Through 01-10-2019",

}

Pfeiffer, P, Bjerregaard, JK, Qvortrup, C, Sorbye, H, Glimelius, B & Kersten, C 2019, 'Updated results of NORDIC 8, a randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer', Annals of Oncology, bind 30, nr. Suppl. 5, 550P, s. 208. https://doi.org/10.1093/annonc/mdz246.027

Updated results of NORDIC 8, a randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer. / Pfeiffer, P.; Bjerregaard, J. K.; Qvortrup, C. et al.
I: Annals of Oncology, Bind 30, Nr. Suppl. 5, 550P, 10.2019, s. 208.

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

TY - ABST

T1 - Updated results of NORDIC 8, a randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer

AU - Pfeiffer, P.

AU - Bjerregaard, J. K.

AU - Qvortrup, C.

AU - Sorbye, H.

AU - Glimelius, B.

AU - Kersten, C.

PY - 2019/10

Y1 - 2019/10

U2 - 10.1093/annonc/mdz246.027

DO - 10.1093/annonc/mdz246.027

M3 - Conference abstract in journal

SN - 0923-7534

VL - 30

SP - 208

JO - Annals of Oncology

JF - Annals of Oncology

IS - Suppl. 5

M1 - 550P

T2 - 44th Congress of the European Society for Medical Oncology

Y2 - 27 September 2019 through 1 October 2019

ER -